These findings indicate again that the comprehensive examination of cell metabolism, as accomplished by 1H magnetic resonance (MRS) imaging, should prove effective in the detection of BTK inhibitor response and resistance in clinical settings, as we see in our in vivo preclinical MCL models (Fig. 5). The gene discussed is BTK; the disease is mantle cell lymphoma.